a b s t r a c t
A harmine-derived beta-carboline, CM16, inhibits cancer cells growth through its effects on protein synthesis, as described in "A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis" (Carvalho et al., 2017) [1] . This data article provides accompanying data on CM16 cytostatic evaluation in cancer cells as well as data related to its effects on transcription and translation. After confirming the cytostatic effect of CM16, we investigated its ability to arrest the cell cycle in the glioma Hs683 and SKMEL-28 melanoma cell lines but no modification was evidenced. According to the global protein synthesis inhibition induced by CM16 [1] , transcription phase, a step prior to mRNA translation, evaluated by labelled nucleotide incorporation assay was not shown to be affected under CM16 treatment in the two cell lines. By contrast, mRNA translation and particularly the initiation step were shown to be targeted by CM16 in [1] As in the description of the data and materials and methods
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Lab. The data presented shows that different methods add to and enrich the investigation of the mechanism of action of proteins synthesis inhibitors in cancer cells. Therefore, these approaches might be useful in similar studies.
Data
Firstly, data on CM16-induced cytostatic effects is presented. As shown in [1] CM16 displays cytostatic effects at its IC 50 in glioma Hs683, melanoma SKMEL-28 and breast adenocarcinoma MDA-MB-231 cells. Thus, CM16 effect on the cell cycle of both glioma Hs683 (Fig. 1A ) cells and SKMEL-28 (Fig. 1B) are presented. After data showing CM16 inhibiting translation [1] , further investigation on the effects of CM16 on newly synthesized mRNA (transcription) were carried out and generated the data here shown ( Fig. 2A-B) . CM16 effects on PERK activity, is shown in Fig. 3 . The data on Table 1 refers to the genes related to translation that were analyzed for their transcriptomic expression in the cell lines most and least sensitive to CM16 effects, according to the NCI 60-cell-line growth inhibitory evaluation [1] . 
Experimental design, materials and methods

Cell lines and compound
The human cancer cell lines, oligodendroglioma Hs683 (ATCC code HTB-138) and melanoma SKMEL-28 (ATCC code HTB-72) were herein used. Cells were cultivated at 37°C with 5% CO 2 in RPMI culture medium supplemented with 10% FBS, 200U penicillin-streptomycin, 0.1 mg/ml gentamicin and 4 mM L-glutamine. CM16 was synthetized as previously described [2] and the experiments were designed with the cell lines described above treated with different concentrations of CM16, based on its IC 50 .
Analysis of CM16 effects on cell cycle
Cell cycle analysis was performed with flow cytometry through the measurements of DNA content with propidium iodide. Hs683 and SKMEL-28 were seeded in cell culture flasks and left untreated or treated with CM16 at its respective IC 50 in each cell line for 24 h, 48 h and 72 h. The samples were then centrifuged (10 min, 1500 rcf, 4°C), resuspended in PBS and pellets were resuspended in cold ethanol 70% for fixation. Staining with 0.08 mg/ml propidium iodide solution (0.08 mg/ml PI; 0.2 mg/ ml RNAse in PBS) followed after a PBS wash. The samples were incubated at 37°C for 30 min and stored at 4°C for a few hours. Analysis was performed with the Cell Lab Quanta (Beckman Coulter, Analis, Suarlée, Belgium). The experiment was performed once in quadruplicate.
Analysis of CM16 effects on transcription
Neosynthesized RNA was evaluated through incorporation of a nucleoside analog, 5-ethynyl-uridine, using the Click iT-RNA HCS (Invitrogen, Life Technologies, Merelbeke, Belgium). The alkynecontaining nucleosides react with a fluorescent dye containing the azide moiety after their incorporation into cellular RNA. Briefly, Hs683 or SKMEL-28 cells were seeded and after attachment they were either left untreated (negative control) or treated with CM16 or the positive control actinomycin (Life Technologies, Paisley, UK). After the treatment with the analog 5-ethynyl uridine (4 mM) for two h, the cells were fixed, stained (Alexa Fluor 488 and 594) and fluorescence readings (ex/em: 495/ 520 nm) were carried out in microplate reader (SynergyMX Biotek, Winooski, USA: ex/em: 350/ 460 nm). Normalization according to cell number was carried out as described in the user manual with Hoescht counterstaining. The experiment was performed once in sextuplicate.
PERK inhibition
PERK activity was evaluated by the Life Technologies screening service (Lantha Screen, Madison, USA). The in vitro assay used is based on FRET between a terbium-labeled antibody and the phosphorylated product of the active kinase: TR-FRET increases proportionally to their binding and thereby to the quantity of the phosphorylated product. CM16 compound at different concentrations or the control solutions were mixed with the kinase/substrate/ATP mixture into the wells. After 60 min of reaction at room temperature, the detection mix was added and left to equilibrate for an h prior to fluorescence reading.
